-
Imatinib hydrochloride: Assay Workflows
2026-08-25
This scenario-based guide helps researchers interpret viability and proliferation results when using Imatinib hydrochloride, including SKU A3487, across CML and GIST models. It connects target-level potency, DMSO handling, controls, and vendor-selection criteria to practical assay decisions.
-
DiscoveryProbe™ Protease Inhibitor Library Guide
2026-08-24
A scenario-driven guide to using DiscoveryProbe™ Protease Inhibitor Library (SKU L1035) in cell viability, proliferation, cytotoxicity, and mechanistic screening workflows. It explains assay compatibility, controls, interpretation, and practical vendor-selection considerations for protease inhibition studies.
-
MK-571 (L-660,711) Assay Workflows
2026-08-24
Build cleaner inflammation experiments by separating cysteinyl leukotriene receptor signaling from ABCC1/MRP1 transport effects. This practical guide covers airway pharmacology, macrophage chemoprotection, formulation, controls, and troubleshooting for MK-571.
-
Streptozotocin Workflow for Diabetes Models
2026-08-23
Streptozotocin, or STZ, provides a practical route to reproducible pancreatic β-cell injury and experimental diabetes mellitus induction. This workflow connects model establishment with painful diabetic neuropathy assays, including microglial TBK1–pyroptosis readouts, while emphasizing formulation control and troubleshooting.
-
Gemcitabine HCl: Reliable Cytotoxicity Workflows
2026-08-22
This scenario-based guide shows how Gemcitabine HCl, SKU A1402, can support better-planned cytotoxicity, DNA replication inhibition, and pancreatic cancer studies. It connects concentration selection, solution handling, data interpretation, and MRI-guided in vivo validation without treating one assay endpoint as a substitute for another.
-
Q-VD(OMe)-OPh in Apoptosis Research
2026-08-22
Q-VD(OMe)-OPh is a broad-spectrum pan-caspase inhibitor for testing caspase dependence in apoptosis assays. The compound, also called quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone, combines recombinant-caspase potency with practical solvent and storage guidance.
-
CHI3L1-IN-5: From Target to Astrocyte Rescue
2026-08-21
CHI3L1-IN-5 (Compound Z17) is a selective CHI3L1 inhibitor that links NF-κB suppression with restoration of astrocyte amyloid clearance. This article explains the mechanistic evidence, assay logic, translational value, and practical limitations behind its use in Alzheimer’s disease research.
-
Cefepime in CNS Infection and Resistance Models
2026-08-20
Cefepime (BMY-28142) offers a useful bridge between blood-brain barrier-aware infection models and contemporary resistance research. This article outlines how translational teams can use the compound to connect exposure, bacterial killing, neurotoxicity risk, and carbapenemase-mediated transmission dynamics.
-
Sodium Picosulfate and the Gut–Liver–Brain Axis
2026-08-20
Sodium Picosulfate is best understood not only as a bowel-output reagent, but also as a controllable perturbation of intestinal water and electrolyte handling. This thought-leadership article connects its established constipation-research utility with gut–liver–brain studies, using the 2025 [18F]PBR146 neuroinflammation work as a framework while clearly separating evidence from hypothesis.
-
Anagliptin (SK-0403): DPP-4 and Vascular Research
2026-08-19
Anagliptin (SK-0403) is a potent, selective, orally active DPP-4 inhibitor reported to have an IC50 of 3.8 nM in the supplier assay. Rabbit-aorta experiments further associate its vasorelaxation with Kv channel activity and SERCA pump function, while separating those findings from clinical efficacy.
-
EPZ5676: Practical DOT1L Inhibitor Workflows
2026-08-19
EPZ5676 combines subnanomolar DOT1L potency with strong methyltransferase selectivity, making it a practical tool for linking H3K79 methylation inhibition to MLL-rearranged leukemia phenotypes. This guide covers formulation, biochemical and cellular workflows, orthogonal validation, and troubleshooting for reproducible results.
-
Gamithromycin PK/PD Cutoffs in Piglet H. parasuis
2026-08-18
Zhou et al. integrated susceptibility surveillance, serum pharmacodynamics, piglet pharmacokinetics, and population dose modeling to define epidemiological and PK/PD cutoffs for gamithromycin against Haemophilus parasuis. The study links an AUC24h/MIC exposure index to bacteriological outcomes and shows that a modest adjustment above the marketed dose could improve target attainment.
-
HSP90 Regulation of RNA Foci in DM1
2026-08-18
A microscopy-based small-molecule screen identified HSP90 as a differentiation-dependent regulator of DMPK mRNA and toxic CUG-repeat RNA foci in myotonic dystrophy type 1 cells. Genetic validation and pathway analysis connected HSP90 activity to p-STAT3 in undifferentiated myoblasts, while differentiated cells showed an opposite, p-STAT3-independent response.
-
Trelagliptin Succinate: From Glycemia to Translation
2026-08-17
Trelagliptin succinate, also known as SYR-472 succinate, offers translational researchers a framework for linking selective DPP-4 enzyme inhibition with incretin biology, adipocyte insulin signaling, and practical diabetes mellitus research workflows.
-
Ratiometric Imaging of Amyloid-β Fibrils
2026-08-17
The reference study introduces dual-emissive tris-heteroleptic ruthenium complexes for ratiometric detection and confocal imaging of Aβ fibrils. By combining an aggregation-responsive phosphorescence signal with a comparatively stable fluorescence reference, the approach improves interpretability while revealing different responses to Aβ40 and Aβ42 assemblies.